Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "H2AZ1 divergent transcript" (H2AZ1-DT) refers to an RNA molecule produced by divergent (typically non-coding, often antisense or bidirectional) transcription at the promoter region of the *H2A.Z.1* (H2AFZ) gene. Such divergent transcripts are a widespread feature of eukaryotic chromatin structure and are especially prominent at nucleosome-depleted regions flanked by nucleosomes incorporating the histone variant H2A.Z[3]. While H2A.Z.1 is a well-studied histone protein involved in gene regulation, DNA repair, and chromatin dynamics[1][5], "H2AZ1 divergent transcript" itself is not a protein-coding gene, does not encode a therapeutic target, and has not been shown to possess direct biological or disease relevance. Instead, it arises as a byproduct or potential regulator of the complex transcriptional landscape near gene promoters and terminators[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on H2A.Z.1 divergent transcript (H2AZ1-DT).